Gilead to buy cancer drugmaker Immunomedics for $21 billion

(Reuters) – Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining acce…
Read More